Navigation
The Company
Our Science
mTOR Pathway
TSC1
&
TSC2
nab
Technology Platform
Publications and Abstracts
Our Medicine
Our Medicine
Advanced Malignant PEComa
Pipeline
Patients
Overview
Patient Advocacy
Clinical Trials
Contact Us
General Contact
For Healthcare Professionals
Careers
Distinct Pharmacokinetics, Tissue Distribution and CNS Penetration of ABI-009 (
nab
-Sirolimus)
Home
Distinct Pharmacokinetics, Tissue Distribution and CNS Penetration of ABI-009 (nab-Sirolimus)
Next Post
Previous Post
Distinct Pharmacokinetics, Tissue Distribution and CNS Penetration of ABI-009 (
nab
-Sirolimus)
April 20, 2019
/
Publications
Like
this post!
Share
the Post
About
the Author
Related
Posts
nab
-Sirolimus in Patients with Malignant PEComa Previously Treated With mTOR Inhibitors: Emerging Experience From An Expanded Access Program
Read More
Neil Desai, PhD
PRECISION 1: A phase 2, multicenter, open-label tumor-agnostic trial of
nab
-sirolimus for malignant solid tumors harboring pathogenic inactivating alterations in
TSC1
and
TSC2
Read More
Stephen Rodin, JD
Response to Treatment With
nab
-Sirolimus Among Patients With Malignant PEComa of Uterine Origin: A Subanalysis From AMPECTÂ
Phase 2, multicenter, open-label basket trial of
nab
-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in
TSC1
or
TSC2
genes (PRECISION I)
Aadi Bioscience Announces Collaborations with Next Generation Sequencing Leaders
Phase 2, Multicenter, Open-label Basket Trial of
nab
-Sirolimus for Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in
TSC1
and
TSC2
(PRECISION1)
Comments
Comments are closed.
Next Post
Previous Post
Comments
Comments are closed.